279 related articles for article (PubMed ID: 32124385)
1. Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
Chevalier LM; Billaud A; Fronteau S; Dauvé J; Patsouris A; Verriele V; Morel A
Mol Diagn Ther; 2020 Apr; 24(2):233-243. PubMed ID: 32124385
[TBL] [Abstract][Full Text] [Related]
2. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
3. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
[TBL] [Abstract][Full Text] [Related]
4. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
5. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
6. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
7. Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
Billaud A; Chevalier LM; Augereau P; Frenel JS; Passot C; Campone M; Morel A
Genome Med; 2021 Nov; 13(1):174. PubMed ID: 34749799
[TBL] [Abstract][Full Text] [Related]
8. Reclassifying BRCA1 c.4358-2A > G and BRCA2 c.475 + 5G > C variants from "Uncertain Significance" to "Pathogenic" based on minigene assays and clinical evidence.
Ning Y; Zhang Y; Tian T; Chen Y; Wang J; Lei K; Cui Z
J Cancer Res Clin Oncol; 2024 Feb; 150(2):62. PubMed ID: 38300310
[TBL] [Abstract][Full Text] [Related]
9. The BRCA1 c.5434C->G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements.
Gaildrat P; Krieger S; Théry JC; Killian A; Rousselin A; Berthet P; Frébourg T; Hardouin A; Martins A; Tosi M
J Med Genet; 2010 Jun; 47(6):398-403. PubMed ID: 20522429
[TBL] [Abstract][Full Text] [Related]
10. Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18.
Fraile-Bethencourt E; Díez-Gómez B; Velásquez-Zapata V; Acedo A; Sanz DJ; Velasco EA
PLoS Genet; 2017 Mar; 13(3):e1006691. PubMed ID: 28339459
[TBL] [Abstract][Full Text] [Related]
11. RNA analysis of cancer predisposing genes in formalin-fixed paraffin-embedded tissue determines aberrant splicing.
Jansen AM; van der Klift HM; Roos MA; van Eendenburg JD; Tops CM; Wijnen JT; Hes FJ; Morreau H; van Wezel T
Eur J Hum Genet; 2018 Aug; 26(8):1143-1150. PubMed ID: 29706640
[TBL] [Abstract][Full Text] [Related]
12. Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel.
Salvati A; Carnevali I; Alexandrova E; Facchi S; Ronchi S; Libera L; Sahnane N; Memoli D; Lamberti J; Amabile S; Pepe S; Tarallo R; Sessa F; Weisz A; Tibiletti MG; Rizzo F
Exp Mol Pathol; 2022 Oct; 128():104833. PubMed ID: 36165864
[TBL] [Abstract][Full Text] [Related]
13. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.
Théry JC; Krieger S; Gaildrat P; Révillion F; Buisine MP; Killian A; Duponchel C; Rousselin A; Vaur D; Peyrat JP; Berthet P; Frébourg T; Martins A; Hardouin A; Tosi M
Eur J Hum Genet; 2011 Oct; 19(10):1052-8. PubMed ID: 21673748
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
Hum Mutat; 2019 Dec; 40(12):2296-2317. PubMed ID: 31343793
[TBL] [Abstract][Full Text] [Related]
15. Multiplex PCR and NGS-based identification of mRNA splicing variants: Analysis of BRCA1 splicing pattern as a model.
Hojny J; Zemankova P; Lhota F; Sevcik J; Stranecky V; Hartmannova H; Hodanova K; Mestak O; Pavlista D; Janatova M; Soukupova J; Vocka M; Kleibl Z; Kleiblova P
Gene; 2017 Dec; 637():41-49. PubMed ID: 28919163
[TBL] [Abstract][Full Text] [Related]
16. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
Fumagalli C; Rappa A; Casadio C; Betella I; Colombo N; Barberis M; Guerini-Rocco E
J Clin Pathol; 2020 Mar; 73(3):168-171. PubMed ID: 31537627
[TBL] [Abstract][Full Text] [Related]
18. Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
Vos JR; Fakkert IE; de Hullu JA; van Altena AM; Sie AS; Ouchene H; Willems RW; Nagtegaal ID; Jongmans MCJ; Mensenkamp AR; Woldringh GH; Bulten J; Leter EM; Kets CM; Simons M; Ligtenberg MJL; Hoogerbrugge N;
J Natl Cancer Inst; 2020 Feb; 112(2):161-169. PubMed ID: 31076742
[TBL] [Abstract][Full Text] [Related]
19. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
20. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
